 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12...75767778798081828384858687» |
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date, Trial primary completion date, HEOR: Effectiveness or Orthopedic Intervention in Osteoporosis Management After a Fracture of the Hip With Cost-Benefit Analysis (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=360, Not yet recruiting, Sponsor: Shaare Zedek Medical Center
Initiation date: Jan 2015 --> Jan 2017 | Trial primary completion date: Jan 2016 --> Jan 2018
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed, Enrollment change: Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis (clinicaltrials.gov) - Apr 19, 2016
P2, N=63, Active, not recruiting, Sponsor: Ersi Voskaridou
Initiation date: Jan 2015 --> Jan 2017 | Trial primary completion date: Jan 2016 --> Jan 2018 Recruiting --> Active, not recruiting | N=80 --> 63
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Osteoclast Inhibition and Bone Formation (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=75, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | N=80 --> 63 Recruiting --> Active, not recruiting
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New trial: Persistence With Prolia (clinicaltrials.gov) - Apr 8, 2016
P=N/A, N=935, Completed, Sponsor: Amgen
- Prolia (denosumab) / Amgen, Xofigo (radium Ra-223 dichloride) / Bayer
Trial primary completion date, Combination therapy, Metastases: Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer (clinicaltrials.gov) - Apr 4, 2016
P2, N=36, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2017 --> Feb 2018
- || zoledronic acid / Generic mfg.
Enrollment change, Trial initiation date, Trial primary completion date, Adverse events: Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA (clinicaltrials.gov) - Mar 29, 2016
P=N/A, N=2100, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Feb 2017 --> Feb 2018 N=3600 --> 2100 | Initiation date: Jan 2012 --> Oct 2011 | Trial primary completion date: Dec 2018 --> Sep 2019
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: REaCT-BTA: 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (clinicaltrials.gov) - Mar 29, 2016
P4, N=250, Not yet recruiting, Sponsor: Ottawa Hospital Research Institute
- |||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion: Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density (clinicaltrials.gov) - Mar 23, 2016
P2, N=419, Completed, Sponsor: Amgen
N=3600 --> 2100 | Initiation date: Jan 2012 --> Oct 2011 | Trial primary completion date: Dec 2018 --> Sep 2019 Active, not recruiting --> Completed
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Denosumab and Teriparatide Study (DATA-HD and DATA-EX) (clinicaltrials.gov) - Mar 23, 2016
P4, N=70, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Oct 2019
- Prolia (denosumab) / Amgen, Enbrel (etanercept) / Pfizer, Amgen
Trial termination: Effects of Denosumab on the Pharmacokinetics of Etanercept (clinicaltrials.gov) - Mar 9, 2016
P1, N=19, Terminated, Sponsor: Amgen
Trial primary completion date: Dec 2016 --> Oct 2019 Active, not recruiting --> Terminated; Lack of enrollment.
- |||| Prolia (denosumab) / Amgen
Trial completion, Metastases: Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates (clinicaltrials.gov) - Feb 27, 2016
P2, N=111, Completed, Sponsor: Amgen
Active, not recruiting --> Terminated; Lack of enrollment. Active, not recruiting --> Completed
- |||| Prolia (denosumab) / Amgen
Trial completion: Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis (clinicaltrials.gov) - Feb 27, 2016
P2, N=227, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Prolia (denosumab) / Amgen
Trial completion, Metastases: Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer (clinicaltrials.gov) - Feb 27, 2016
P2, N=255, Completed, Sponsor: Amgen
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||||||| Prolia (denosumab) / Amgen
Trial completion: Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis (clinicaltrials.gov) - Feb 27, 2016
P3, N=332, Completed, Sponsor: Amgen
No longer recruiting --> Completed Active, not recruiting --> Completed
- |||| Prolia (denosumab) / Amgen
Trial completion: Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density (clinicaltrials.gov) - Feb 27, 2016
P2, N=412, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Completed
- |||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial primary completion date: FRAME: Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Feb 23, 2016
P3, N=7180, Active, not recruiting, Sponsor: Amgen
Recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2015
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders (clinicaltrials.gov) - Feb 23, 2016
P1/2, N=24, Not yet recruiting, Sponsor: Indiana University
Trial primary completion date: Dec 2016 --> Dec 2015 Initiation date: Jun 2015 --> Jun 2017
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI (clinicaltrials.gov) - Feb 17, 2016
P3, N=150, Recruiting, Sponsor: Amgen
Initiation date: Jun 2015 --> Jun 2017 Trial primary completion date: Aug 2020 --> Jun 2019
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: PILOTE: Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia (clinicaltrials.gov) - Feb 16, 2016
P=N/A, N=750, Recruiting, Sponsor: Amgen
Trial primary completion date: Aug 2020 --> Jun 2019 Trial primary completion date: Apr 2018 --> Mar 2017
- || Prolia (denosumab) / Amgen
Enrollment closed: Denosumab Safety Assessment in Multiple Observational Databases (clinicaltrials.gov) - Feb 16, 2016
P=N/A, N=575462, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Apr 2018 --> Mar 2017 Recruiting --> Active, not recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P1 trial: Denosumab for Prevention of Bone Complications After Bone Marrow Transplantation in Children (clinicaltrials.gov) - Feb 9, 2016
P1, N=12, Not yet recruiting, Sponsor: St. Justine's Hospital
- Prolia (denosumab) / Amgen
Trial primary completion date: Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium (clinicaltrials.gov) - Feb 8, 2016
P2, N=33, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2013 --> Sep 2012
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement (clinicaltrials.gov) - Feb 5, 2016
P4, N=15, Recruiting, Sponsor: Amgen
Trial primary completion date: Aug 2013 --> Sep 2012 Trial primary completion date: Sep 2017 --> May 2017
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date, Metastases: Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer (clinicaltrials.gov) - Feb 4, 2016
P3, N=129, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Sep 2017 --> May 2017 Trial primary completion date: Jun 2017 --> Dec 2016
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: TNFSF11 Inhibition and Fertility: a Prospective Study (clinicaltrials.gov) - Feb 4, 2016
P2, N=15, Active, not recruiting, Sponsor: Martin Blomberg Jensen
Trial primary completion date: Jun 2017 --> Dec 2016 Recruiting --> Active, not recruiting
- || Prolia (denosumab) / Amgen
Trial primary completion date, Combination therapy, Metastases: Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Feb 2, 2016
P2, N=226, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2017 --> Nov 2016
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors (clinicaltrials.gov) - Feb 2, 2016
P3, N=487, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Apr 2017 --> Nov 2016 Trial primary completion date: Dec 2015 --> Feb 2015
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open, Trial initiation date: Denosumab for Treating Periprosthetic Osteolysis. (clinicaltrials.gov) - Jan 28, 2016
P2, N=110, Recruiting, Sponsor: Olof Skoldenberg
Trial primary completion date: Dec 2015 --> Feb 2015 Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Aug 2015
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Osteoclast Inhibition and Bone Formation (clinicaltrials.gov) - Jan 6, 2016
P=N/A, N=75, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Aug 2015 Not yet recruiting --> Recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study (clinicaltrials.gov) - Dec 17, 2015
P2, N=20, Not yet recruiting, Sponsor: Children's Hospital of Eastern Ontario
- |||| Prolia (denosumab) / Amgen
Trial primary completion date: Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) (clinicaltrials.gov) - Dec 5, 2015
P3, N=4509, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2016 --> Nov 2017
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement (clinicaltrials.gov) - Dec 5, 2015
P4, N=15, Recruiting, Sponsor: Amgen
Trial primary completion date: Oct 2016 --> Nov 2017 Not yet recruiting --> Recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: The Efficacy of Denosumab in Active Crohn's Disease (clinicaltrials.gov) - Dec 4, 2015
P1/2, N=30, Recruiting, Sponsor: University of Manitoba
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen
Biomarker, New P2 trial: Denosumab and MRI Breast Imaging (clinicaltrials.gov) - Nov 24, 2015
P2, N=44, Recruiting, Sponsor: Stony Brook University
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: AOST1321: Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Nov 17, 2015
P2, N=90, Recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Observational Study of Denosumab (Prolia (clinicaltrials.gov) - Nov 10, 2015
P=N/A, N=1501, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab (clinicaltrials.gov) - Nov 9, 2015
P4, N=60, Active, not recruiting, Sponsor: Health Research, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Denosumab China Phase III Study (clinicaltrials.gov) - Oct 26, 2015
P3, N=487, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement (clinicaltrials.gov) - Oct 22, 2015
P4, N=15, Not yet recruiting, Sponsor: Amgen
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date, Metastases: ABCSG-18: Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy (clinicaltrials.gov) - Oct 7, 2015
P3, N=3420, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Mar 2014
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
New P3 trial: DIBLAN: Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa (clinicaltrials.gov) - Oct 2, 2015
P3, N=84, Not yet recruiting, Sponsor: University Hospital, Montpellier
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis (clinicaltrials.gov) - Sep 24, 2015
P2, N=90, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Oct 2014 --> Mar 2014 Trial primary completion date: Feb 2015 --> Feb 2016
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial suspension, Trial primary completion date: Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo (clinicaltrials.gov) - Sep 24, 2015
P4, N=90, Suspended, Sponsor: Medical University of Vienna
Trial primary completion date: Feb 2015 --> Feb 2016 Active, not recruiting --> Suspended | Trial primary completion date: Dec 2014 --> Sep 2015
- Prolia (denosumab) / Amgen, Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed, Enrollment change, Trial primary completion date: Effects of Denosumab on the Pharmacokinetics of Etanercept (clinicaltrials.gov) - Sep 24, 2015
P1, N=17, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Suspended | Trial primary completion date: Dec 2014 --> Sep 2015 Recruiting --> Active, not recruiting | N=44 --> 17 | Trial primary completion date: Sep 2015 --> Jan 2016
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis (clinicaltrials.gov) - Sep 24, 2015
P2, N=80, Recruiting, Sponsor: Ersi Voskaridou
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New trial: Osteoclast Inhibition and Bone Formation (clinicaltrials.gov) - Sep 18, 2015
P=N/A, N=75, Not yet recruiting, Sponsor: Mayo Clinic
- ||||||| Prolia (denosumab) / Amgen
Trial completion: Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis (clinicaltrials.gov) - Sep 16, 2015
P3, N=4550, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=44 --> 17 | Trial primary completion date: Sep 2015 --> Jan 2016 Active, not recruiting --> Completed
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion, Trial primary completion date: A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Sep 3, 2015
P3, N=394, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jul 2015
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: PILOTE: Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia (clinicaltrials.gov) - Aug 18, 2015
P=N/A, N=750, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jul 2015 Not yet recruiting --> Recruiting
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=600, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed